Literature DB >> 31186850

Hepatitis C viral infection in difficult-to-treat populations: An overview.

Nezam H Afdhal1.   

Abstract

Entities:  

Year:  2012        PMID： 31186850      PMCID： PMC6499269          DOI： 10.1002/cld.57

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  15 in total

1.  Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

Authors:  Peter Ferenci; Michael W Fried; Mitchell L Shiffman; Coleman I Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampero Carosi; Daniel Dhumeaux; Antonio Craxì; Monique Chaneac; K Rajender Reddy
Journal:  J Hepatol       Date:  2005-09       Impact factor: 25.083

2.  Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.

Authors:  Donald M Jensen; Timothy R Morgan; Patrick Marcellin; Paul J Pockros; K Rajender Reddy; Stephanos J Hadziyannis; Peter Ferenci; Andrew M Ackrill; Bernard Willems
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

3.  Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

Authors:  Hari S Conjeevaram; Michael W Fried; Lennox J Jeffers; Norah A Terrault; Thelma E Wiley-Lucas; Nezam Afdhal; Robert S Brown; Steven H Belle; Jay H Hoofnagle; David E Kleiner; Charles D Howell
Journal:  Gastroenterology       Date:  2006-08       Impact factor: 22.682

4.  Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy.

Authors:  Gregory T Everson; James Trotter; Lisa Forman; Marcelo Kugelmas; Arthur Halprin; Barbara Fey; Catherine Ray
Journal:  Hepatology       Date:  2005-08       Impact factor: 17.425

5.  A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation.

Authors:  Jeffrey S Crippin; Tim McCashland; Norah Terrault; Patricia Sheiner; Michael R Charlton
Journal:  Liver Transpl       Date:  2002-04       Impact factor: 5.799

6.  Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.

Authors:  Angelo Iacobellis; Massimo Siciliano; Francesco Perri; Brigida E Annicchiarico; Gioacchino Leandro; Nazario Caruso; Laura Accadia; Giuseppe Bombardieri; Angelo Andriulli
Journal:  J Hepatol       Date:  2006-10-20       Impact factor: 25.083

7.  Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation.

Authors:  Ryan M Thomas; John J Brems; Grace Guzman-Hartman; Sherri Yong; Patricia Cavaliere; David H Van Thiel
Journal:  Liver Transpl       Date:  2003-09       Impact factor: 5.799

8.  Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.

Authors:  Raymond T Chung; Janet Andersen; Paul Volberding; Gregory K Robbins; Tun Liu; Kenneth E Sherman; Marion G Peters; Margaret J Koziel; Atul K Bhan; Beverly Alston; Dodi Colquhoun; Tom Nevin; George Harb; Charles van der Horst
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

9.  Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.

Authors:  Xavier Forns; Montserrat García-Retortillo; Trinidad Serrano; Anna Feliu; Francisco Suarez; Manuel de la Mata; Juan Carlos García-Valdecasas; Miquel Navasa; Antoni Rimola; Juan Rodés
Journal:  J Hepatol       Date:  2003-09       Impact factor: 25.083

10.  Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.

Authors:  Vito Di Marco; Piero Luigi Almasio; Donatella Ferraro; Vincenza Calvaruso; Giuseppe Alaimo; Sergio Peralta; Rosa Di Stefano; Antonio Craxì
Journal:  J Hepatol       Date:  2007-06-27       Impact factor: 25.083
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.